First & only once-daily triple therapy in a single inhaler for adult patients with ASTHMA
For patients aged 18+ who continue to experience symptoms on an ICS/LABA
TRELEGY 100/62.5/25 mcg
TRELEGY 200/62.5/25 mcg
Design: A 24- to 52-week, randomized, double-blind, active-controlled, parallel-group, multicenter study that evaluated the safety and efficacy of TRELEGY 100/62.5/25 mcg and TRELEGY 200/62.5/25 mcg compared with BREO 100/25 mcg and BREO 200/25 mcg, respectively (each administered once daily in the morning).
Patients: Patients ≥18 years were eligible if they had inadequately controlled asthma (ACQ-6 score ≥1.5) while receiving daily ICS/LABA (ICS dose >250 mcg fluticasone propionate or equivalent) for ≥12 weeks pre-study. After a 5-week run-in and stabilization period, 2436 patients were randomized to treatment (mean age 53 years, baseline mean percent predicted FEV1 68%).